Login / Signup

Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynäkologische Onkologie intergroup analysis.

Bich Doan Nguyen-SträuliJoanna BaumPhilipp Meyer-WilmesAnne KreklauChristina BuschmannNabila El OuardiChristina FotopoulouMichael HummelRadoslav ChekerovElena BraicuJalid SehouliKlaus Pietzner
Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022)
Adequate structure for BRCA/HR deficiency testing, and systematic education programs are needed to prevent delay in counseling and undertreatment of women with epithelial ovarian cancer. In Germany, a combination of olaparib and bevacizumab seems to be the preferred treatment in the first-line setting.
Keyphrases